C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer
| Status: | Completed |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/3/2014 |
| Start Date: | July 2014 |
| End Date: | December 2014 |
NCI 8701: A Pilot Study Utilizing C11 Alpha Methyl Tryptophan (AMT) PET Functional Imaging in Patients With Metastatic Invasive Breast Cancer Treated With 1 Methyl D Tryptophan Plus the Ad p53 DC Vaccine
The purpose of this research project is to create images of where and how the amino acid
(the building blocks of proteins)Tryptophan is processed in normal and abnormal tissue in
the patient's body. Tryptophan is a normal building block of proteins in the body. Sometimes
in the case of cancer and other diseases, Tryptophan is processed abnormally, and possible
treatments for this abnormality are of great interest because of the potential to improve
cancer care.
(the building blocks of proteins)Tryptophan is processed in normal and abnormal tissue in
the patient's body. Tryptophan is a normal building block of proteins in the body. Sometimes
in the case of cancer and other diseases, Tryptophan is processed abnormally, and possible
treatments for this abnormality are of great interest because of the potential to improve
cancer care.
Coordinating Center: Southeast Phase 2 Consortium (SEP2C), Moffitt Cancer Center.
Research participation involves up to three experimental imaging examination visits in
radiology: a baseline before the patient starts a cancer treatment, a follow-up a few days
later, and a later follow up to see how the treatment may affect normal or abnormal
processing of Tryptophan.
The research imaging results will be linked with other evidence of the patient's disease,
but will not effect their care.
Research participation involves up to three experimental imaging examination visits in
radiology: a baseline before the patient starts a cancer treatment, a follow-up a few days
later, and a later follow up to see how the treatment may affect normal or abnormal
processing of Tryptophan.
The research imaging results will be linked with other evidence of the patient's disease,
but will not effect their care.
Inclusion Criteria:
- Patients must be enrolled on the NCI 8461/MCC 16025 study.
- Consent for participation in this companion imaging study and be able to successfully
complete a minimum of two AMT PET/CT scans.
Exclusion Criteria:
- Patients must not meet any of the exclusion criteria for the NCI 8461/ MCC 16025
study.
- Not have any medical conditions prohibiting the successful completion of a minimum of
two AMT PET/CT scans.
We found this trial at
1
site
12902 USF Magnolia Dr
Tampa, Florida 33612
Tampa, Florida 33612
(888) 663-3488
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
Click here to add this to my saved trials
